Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 75 Show results per page	View Search Criteria \| Help With Results


1.		Effects of Granulocyte Colony-Stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				D-0140 NCT00169104


2.		Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CSTI571BDE28 NCT00372476


3.		Random Trial for Elderly Patients With NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and over				Other				INJE05-06 NCT00265694

Last Modified: 1/24/2007 First Published: 3/24/2006


4.		Phase III Randomized Study of Sequential Cisplatin and Vinorelbine Ditartrate (CV) Followed By Radical Radiotherapy Versus Concurrent CV Chemoradiotherapy Followed By CV Chemotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer and Good Performance Status

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CRUK-SOCCAR ISRCTN13746987, EU-20602, EUDRACT-2004-001920-19, NCT00309972


5.		Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				75 to 90				Other				IFCT-0501 NCT00298415


6.		Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				SLCSG0501 NCT00300729

Last Modified: 1/14/2009 First Published: 5/5/2006


7.		Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E1505 E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805

Last Modified: 11/30/2006 First Published: 9/15/2006


8.		Phase III Randomized Study of Ifosfamide, Vincristine, and Dactinomycin With or Without Doxorubicin in Pediatric Patients With Non-Metastatic Rhabdomyosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 21				Other				CCLG-EPSSG-RMS-2005 EU-20639, EUDRACT-2005-000217-35, UKCCSG-RMS-2005, NCT00379457


9.		Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 74				Other				HERNATA NCT00430001


10.		Study With Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				19 to 75				Other				CT/02.11 NCT00431106

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute